In an attempt to diversify its portfolio, Lilly has entered into a definitive agreement to acquire Ventyx Biosciences in a deal valued at approximately US$1.2 B. The acquisition will provide Lilly with access to Ventyx’s pipeline of innovative oral therapies targeting inflammatory‑mediated diseases, with a key focus on NLRP3 inhibitors. The move aligns with Lilly’s strategic focus on advancing novel treatments within cardiovascular, renal, and metabolic (CVRM) disease areas, particularly for patients affected by inflammation-driven conditions., as it attempts to build sustainable long‑term growth beyond its blockbuster diabetes and obesity therapy, Mounjaro/Zepbound (tirzepatide).